Literature DB >> 11557032

Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells.

Q Yu1, J H Rose, H Zhang, Y Pommier.   

Abstract

The cellular response to DNA damage involves checkpoint controls that delay cell cycle progression in order to provide time for repair of damaged DNA. Chk2/hCds1 is a recently identified homolog of the yeast Cds1 kinase that is involved in cell cycle checkpoint response to DNA damage. To investigate the functions of Chk2/hCds1 in response to DNA damage in mammalian cells, we established a stable human kidney embryonic cell line (HEK-293) that expresses antisense Chk2/hCds1 (Chk2AS) under the control of an inducible promoter. Cells that express Chk2AS display defective S-phase delay in response to DNA replication-mediated DNA damage induced by the topoisomerase I inhibitor camptothecin. The defective G2 checkpoint was also observed in Chk2AS cells exposed to the DNA damaging agent VP-16 or gamma-radiation. Enhanced apoptosis was observed in Chk2AS cells after exposure to gamma-radiation or camptothecin. No p53 activation was observed after DNA damage in HEK-293 or Chk2AS cells. Our results indicate that perturbation of Chk2/hCds1 expression adversely affects the S- and G2-phase checkpoints following DNA damage or DNA replication block, and suggest that reduced expression of Chk2/hCds1 might promote a p53-independent apoptotic response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557032     DOI: 10.1016/s0014-5793(01)02756-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  26 in total

1.  Zinc-finger protein-targeted gene regulation: genomewide single-gene specificity.

Authors:  Siyuan Tan; Dmitry Guschin; Albert Davalos; Ya-Li Lee; Andrew W Snowden; Yann Jouvenot; H Steven Zhang; Katherine Howes; Andrew R McNamara; Albert Lai; Chris Ullman; Lindsey Reynolds; Michael Moore; Mark Isalan; Lutz-Peter Berg; Bradley Campos; Hong Qi; S Kaye Spratt; Casey C Case; Carl O Pabo; Judith Campisi; Philip D Gregory
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-26       Impact factor: 11.205

2.  Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy.

Authors:  George T Lountos; Andrew G Jobson; Joseph E Tropea; Christopher R Self; Guangtao Zhang; Yves Pommier; Robert H Shoemaker; David S Waugh
Journal:  J Struct Biol       Date:  2011-09-22       Impact factor: 2.867

Review 3.  Repair of topoisomerase I-mediated DNA damage.

Authors:  Yves Pommier; Juana M Barcelo; V Ashutosh Rao; Olivier Sordet; Andrew G Jobson; Laurent Thibaut; Ze-Hong Miao; Jennifer A Seiler; Hongliang Zhang; Christophe Marchand; Keli Agama; John L Nitiss; Christophe Redon
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

4.  Co-abrogation of Chk1 and Chk2 by potent oncolytic adenovirus potentiates the antitumor efficacy of cisplatin or irradiation.

Authors:  F Ye; Z Yang; Y Liu; D Gong; T Ji; J Wang; B Xi; J Zhou; D Ma; Q Gao
Journal:  Cancer Gene Ther       Date:  2014-05-23       Impact factor: 5.987

5.  Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition.

Authors:  Andreas Höglund; Kerstin Strömvall; Yongmei Li; Linus Plym Forshell; Jonas A Nilsson
Journal:  Cell Cycle       Date:  2011-10-15       Impact factor: 4.534

6.  CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.

Authors:  Victoria E Anderson; Michael I Walton; Paul D Eve; Katherine J Boxall; Laurent Antoni; John J Caldwell; Wynne Aherne; Laurence H Pearl; Antony W Oliver; Ian Collins; Michelle D Garrett
Journal:  Cancer Res       Date:  2011-01-15       Impact factor: 12.701

7.  CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.

Authors:  G Zoppoli; S Solier; W C Reinhold; H Liu; J W Connelly; A Monks; R H Shoemaker; O D Abaan; S R Davis; P S Meltzer; J H Doroshow; Y Pommier
Journal:  Oncogene       Date:  2011-07-18       Impact factor: 9.867

8.  Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor.

Authors:  George T Lountos; Joseph E Tropea; Di Zhang; Andrew G Jobson; Yves Pommier; Robert H Shoemaker; David S Waugh
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

9.  2-Deoxy-D-glucose and ferulic acid modulates radiation response signaling in non-small cell lung cancer cells.

Authors:  Venkata Reddy Bandugula; Rajendra Prasad N
Journal:  Tumour Biol       Date:  2012-10-12

10.  Topoisomerase levels determine chemotherapy response in vitro and in vivo.

Authors:  Darren J Burgess; Jason Doles; Lars Zender; Wen Xue; Beicong Ma; W Richard McCombie; Gregory J Hannon; Scott W Lowe; Michael T Hemann
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.